CYP2C9 polymorphism and warfarin dose requirements

Br J Clin Pharmacol. 2002 Apr;53(4):408-9. doi: 10.1046/j.1365-2125.2002.01572_6.x.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Alleles
  • Anticoagulants / administration & dosage*
  • Anticoagulants / therapeutic use
  • Aryl Hydrocarbon Hydroxylases*
  • Cytochrome P-450 CYP2C9
  • Cytochrome P-450 Enzyme System / genetics*
  • Heterozygote
  • Humans
  • Polymorphism, Genetic*
  • Steroid 16-alpha-Hydroxylase*
  • Steroid Hydroxylases / genetics*
  • Warfarin / administration & dosage*
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Warfarin
  • Cytochrome P-450 Enzyme System
  • Steroid Hydroxylases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Steroid 16-alpha-Hydroxylase